1 In 5 Early-Stage Breast Cancer Patients May Not Follow Hormonal Therapy Plan

BOSTON—Postmenopausal women with early-stage, hormone-sensitive breast cancer have a lower risk of disease recurrence when their treatment includes a new class of hormone therapy drugs, yet one out five women prescribed the drugs may not take them regularly, according to a study conducted by researchers at Dana-Farber Cancer Institute and AstraZeneca Pharmaceuticals. Their findings will be presented at the 29th annual San Antonio Breast Cancer Symposium on Saturday, Dec. 16 (Abstract 4044).

>>> Discuss This Story

Back to news